Comparison of Demand for Drugs Used for COVID-19 Treatment and Other Drugs During the Early Phase of the COVID-19 Pandemic in Italy
- 1 February 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (2), e2037060
- https://doi.org/10.1001/jamanetworkopen.2020.37060
Abstract
In February 2020, Italy was the first European country to detect coronavirus disease 2019 (COVID-19) in individuals and rapidly turned into one of the most-affected regions of the world. The National Health Service (NHS), which provides universal coverage to citizens, was challenged as never before in the history of the institution. Because no approved drug was available, patients received potentially effective drugs, participated in clinical trials, accessed compassionate drug use programs, or self-medicated.1 The aim of this study was to evaluate changes in drug demand during the early phase of the COVID-19 outbreak in Italy compared with the period before the outbreak.This publication has 6 references indexed in Scilit:
- Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in ItalyAnnals of Internal Medicine, 2020
- US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020JAMA Internal Medicine, 2020
- Timed intervention in COVID-19 and panic buyingJournal of Retailing and Consumer Services, 2020
- Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United StatesJAMA, 2020
- Faculty Opinions recommendation of Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.Published by H1 Connect ,2020
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)JAMA, 2020